ICU Medical (NASDAQ:ICUI) vs. MiMedx Group (NASDAQ:MDXG) Critical Analysis

MiMedx Group (NASDAQ:MDXG) and ICU Medical (NASDAQ:ICUI) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Risk and Volatility

MiMedx Group has a beta of 1.94, meaning that its share price is 94% more volatile than the S&P 500. Comparatively, ICU Medical has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500.

Valuation & Earnings

This table compares MiMedx Group and ICU Medical”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$348.88 million	3.51	$58.23 million	$0.28	29.64
ICU Medical	$2.38 billion	1.46	-$29.66 million	($4.83)	-29.31

MiMedx Group has higher earnings, but lower revenue than ICU Medical. ICU Medical is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for MiMedx Group and ICU Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	0	0	4	0	3.00
ICU Medical	0	1	3	0	2.75

MiMedx Group presently has a consensus target price of $12.00, indicating a potential upside of 44.58%. ICU Medical has a consensus target price of $199.67, indicating a potential upside of 41.05%. Given MiMedx Group’s stronger consensus rating and higher possible upside, analysts plainly believe MiMedx Group is more favorable than ICU Medical.

Profitability

This table compares MiMedx Group and ICU Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MiMedx Group	23.86%	26.21%	18.15%
ICU Medical	-4.74%	5.05%	2.42%

Insider & Institutional Ownership

79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 96.1% of ICU Medical shares are owned by institutional investors. 1.3% of MiMedx Group shares are owned by company insiders. Comparatively, 6.7% of ICU Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

MiMedx Group beats ICU Medical on 11 of the 14 factors compared between the two stocks.

About MiMedx Group

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins. The company’s patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company’s products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

About ICU Medical

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.